Investigation into the binding domains of platelet factor 4 unlocks new avenues for the design and synthesis of selective sulfated pseudo-tetrasaccharide aminoglycoside ligands
Research article published in European journal of medicinal chemistry (2025)
Abstract
Platelet factor 4 (PF4) is a natural chemokine that binds to negatively charged glycosaminoglycans (GAGs), including the anticoagulant heparin. The formation of the PF4-heparin complex elicits an immune response that results in platelet activation, leading to serious thrombotic complications. This study explores the structure-activity relationships (SAR) of sulfated pseudo-tetrasaccharide aminoglycoside ligands. The binding interactions of these synthetically designed compounds with heparanase (HPSE) and PF4 were systematically elucidated. Through computational design, a library of sulfated aminoglycoside ligands was synthesized in 10-13 steps from readily available paromomycin and neomycin. The SAR studies revealed that hydroxyl-capped ligands interacted with the fondaparinux-binding domain of PF4, while hydrophobic-capped ligands bound to the heparin-binding domain. Notably, steric hindrance imposed by hydrophobic groups impedes the binding of the ligands to PF4's shallow binding site. In contrast, these hydrophobic-capped ligands demonstrated a strong binding affinity for HPSE. The most selective ligands reduced the viability of HPSE-overexpressing cancer cells, highlighting their potential efficacy in modulating the enzymatic activity of HPSE. This SAR study provides a foundational framework for the design of sulfated aminoglycoside-based therapeutics with minimized adverse effects associated with PF4.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Peer-reviewed research on anticoagulant and antithrombotic drug development relevant to leech-derived and synthetic compounds. Indexed in PubMed and verified against the NCBI record.
Why This Matters for Hirudotherapy
This medicinal-chemistry study mapped how synthetically designed sulfated pseudo-tetrasaccharide aminoglycoside ligands bind platelet factor 4 (PF4) and heparanase (HPSE), reporting that hydroxyl-capped ligands engaged PF4's fondaparinux-binding domain while hydrophobic-capped ligands instead bound the heparin-binding domain and HPSE, with the most selective ligands reducing viability of HPSE-overexpressing cancer cells. For hirudotherapy the connection is contextual rather than direct: the PF4-heparin complex described here is the immunological trigger of heparin-associated platelet activation and thrombotic complications, which is precisely the heparin liability that motivates interest in mechanistically distinct, non-heparin anticoagulants such as the leech-derived direct thrombin inhibitor hirudin. This is preclinical, computational and in-vitro work on engineered small molecules with no leech-derived compound or patient data, so it informs the broader anticoagulant-safety landscape only as background and cannot be read as evidence about leech therapy itself.
Citation
Investigation into the binding domains of platelet factor 4 unlocks new avenues for the design and synthesis of selective sulfated pseudo-tetrasaccharide aminoglycoside ligands.
Philip et al. · European journal of medicinal chemistry, 2025
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026